This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, W. W. Articles by Struewing, J. P. Search for Related Content PubMed PubMed Citation Articles by Wang, W. W. Articles by Struewing, J. P.

A Single Nucleotide Polymorphism in the 5' Untranslated Region of RAD51 and Risk of Cancer among BRCA1/2 Mutation Carriers¹

Laboratory of Population Genetics [W. W., S. M. E., D. J. K., J. P. S.], Genetic Epidemiology Branch [M. A. T.], Radiation Epidemiology Branch [M. M. D.], and Biostatistics Branch [R. E. T.], National Cancer Institute, NIH, Bethesda, Maryland 20892; Queensland Institute of Medical Research, Brisbane QLD 4029, Australia [A. B. S., G. C-T.]; South Australian Clinical Genetics Service, Adelaide 5005, Australia [G. S.]; Memorial Sloan Kettering Cancer Center, New York, New York 10021 [P. K., H. P., K. O.]; Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [B. B., M. D., A. K. G.]; and Chaim Sheba Medical Center, Tel Hashomer, Israel 52641 [B. M., H. L., A. C., G. H. Y.]

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
RAD51 colocalizes with both BRCA1 and BRCA2, and genetic variants in RAD51 would be candidate BRCA1/2 modifiers. We searched for RAD51 polymorphisms by sequencing 20 individuals. We compared the polymorphism allele frequencies between female BRCA1/2 mutation carriers with and without breast or ovarian cancer and between population-based ovarian cancer cases with BRCA1/2 mutations to cases and controls without mutations. We discovered two single nucleotide polymorphisms (SNPs) at positions 135 gc and 172 gt of the 5' untranslated region. In an initial group of BRCA1/2 mutation carriers, 14 (21%) of 67 breast cancer cases carried a "c" allele at RAD51:135 gc, whereas 8 (7%) of 119 women without breast cancer carried this allele. In a second set of 466 mutation carriers from three centers, the association of RAD51:135 gc with breast cancer risk was not confirmed. Analyses restricted to the 216 BRCA2 mutation carriers, however, showed a statistically significant association of the 135 "c" allele with the risk of breast cancer (adjusted odds ratio, 3.2; 95% confidence limit, 1.4–40). BRCA1/2 mutation carriers with ovarian cancer were only about one half as likely to carry the RAD51:135 gc SNP. Analysis of the RAD51:135 gc SNP in 738 subjects from an Israeli ovarian cancer case-control study was consistent with a lower risk of ovarian cancer among BRCA1/2 mutation carriers with the "c" allele. We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers. The biochemical basis of this risk modifier is currently unknown.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Genetic factors are important in breast and ovarian cancer, but less than 10% are attributable to the inheritance of mutations in a single gene, such as BRCA1 and BRCA2 (1) . Although relatively uncommon, female carriers of mutations in the BRCA1 and BRCA2 genes are estimated to have breast cancer risks of 37% to over 85% by age 70 and ovarian cancer risks approximately one half as high (2, 3, 4, 5) . Both BRCA1 and BRCA2 appear to confer similarly high risks of female breast cancer, whereas ovarian cancer risk is higher for BRCA1 mutation carriers and male breast cancer risk is largely confined to BRCA2 carriers (1 , 6) . The heterogeneity of risk in breast and ovarian cancer between different families segregating mutations in the same gene and the estimated average risk of breast cancer of about 50% both suggest the existence of important environmental or genetic modifiers of risk. Some potential genetic modifiers have been identified, including rare polymorphisms in H-ras for ovarian cancer (7) and variation in the androgen receptor gene for breast cancer risk (8) .

The precise mechanisms by which mutations in BRCA1/2 predispose to breast and ovarian cancer are unknown. They are large proteins that share little sequence similarity with each other or with other known sequences. Both appear to be involved in double-strand DNA break repair, particularly because of their association with RAD51 (9) . RAD51 is a homologue of the Escherichia coli recA protein and is involved in recombination and the repair of double-strand DNA breaks (10) . RAD51 shares 60% protein identity with the yeast scRad51, which has been studied extensively (10 , 11) . The relative consistency of the findings of BRCA1 and BRCA2 associating with RAD51, their possible complementary roles as DNA damage repair proteins, and the availability of a model organism system in which to investigate findings led us to consider RAD51 as a candidate modifier locus.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Polymorphisms in RAD51 were investigated by complete sequence analysis of the gene in 10 individuals who had developed both breast cancer and at least one other primary cancer obtained from a national cohort of radiological technologists participating in a prospective epidemiological study (12) , and the 5'UTR⁷ was sequenced in an additional 10 individuals (subjects 01 and 02 from each of the Center d’Etude du Polymorphisme Humain families 1331, 1332, 1347, 1362, and 1413; Coriell Institute, Camden, NJ). Sequencing these subjects revealed a gc polymorphism at position 135 and a gt at position 172 of the published cDNA (GenBank accession no. D14134.1)

Two groups were studied to test for allelic association, including: (a) a series of female BRCA1/2 mutation carriers; and (b) Jewish subjects from an Israeli ovarian cancer case-control study. All of the subjects with individually identifiable samples gave informed consent for participation. Study group (a) included all of the known female BRCA1 and/or BRCA2 heterozygous mutation carriers from each of four study centers. Disease associations for the two SNPs were first assessed in two groups of subjects from the NCI. One group was from the Washington Ashkenazi Study, a community-based sample of 86 females who carried the185delAG or 5382 insC mutations in BRCA1 and/or the 6174delT mutation in BRCA2 (3) . The second NCI group consisted of 100 female members of 27 breast/ovarian cancer families with identified BRCA1 or BRCA2 mutations from the NCI Genetic Epidemiology Branch family registry (13) .

To replicate the findings with RAD51:135 gc, study group (a) was expanded to include subjects from three additional centers. Subjects from the Fox Chase Cancer Center were recruited from high-risk and breast cancer clinics at the Fox Chase Cancer Center and affiliated hospitals in the Delaware Valley, as well as through self- and physician-referral. Subjects from Australia were either members of multiple-case families ascertained in family cancer clinics by the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (14) or the South Australian Clinical Genetics Service or from the population-based case-control-family studies of the Australian Breast Cancer Family Study/Cooperative Family Registry for Breast Cancer Studies (15) and the Australian Jewish Breast Cancer Study (16) . All of the Jewish BRCA1/2 mutation carriers ascertained from Memorial Sloan Kettering Cancer Center were also studied.

Study group (b) included a subset of subjects from a case-control study of all of the cases of invasive epithelial ovarian cancer diagnosed among Jews in Israel between 1994–1999 and age- and ethnicity-matched population controls tested for the three founder BRCA1/2 mutations (17 , 18) . For study group (b), RAD51:135 gc SNP typing was completed for 213 (86%) of 249 cases who were BRCA1/2 mutation positive and for random subsets of 304 of the 598 mutation-negative cases and 221 of the 777 mutation-negative controls from this study.

Most BRCA1/2 mutations were identified in the laboratories of the individual study centers using a number of techniques, whereas some were identified by complete sequencing performed at Myriad Genetics Laboratories (Salt Lake City, UT). We were relatively conservative in our definition of mutations, because only two of the 73 included in this study were BRCA1 missense mutations (C61G, observed to cosegregate with disease in multiple families worldwide, and V1713A, an extremely rare variant in a family with a logarithm of the odds score of 1.3 for linkage to BRCA1). The remaining mutations were nonsense, frameshift, splice junction, or large genomic rearrangements. Among group (a) subjects, the two most common mutations were BRCA1:185delAG (n = 216) and BRCA2:6174delT (n = 124).

Laboratory Analysis.
To identify RAD51 polymorphisms, because the genomic structure of RAD51 was unpublished, we extracted total RNA from lymphoblastoid cell lines, performed reverse transcription-PCR, and sequenced the cDNA in overlapping fragments (conditions and primer sequences available on request). The two 5'UTR SNPs identified could be detected in one single-strand conformational polymorphism/heteroduplex analysis assay using genomic DNA as template and the primers 21F (5'-ccgagccctaaggagagtgcggcgcttc-3') and 232R (5'-tactcggtccgcagcgctcctctctccag-3'). Thirty-five samples were sequenced and analyzed with single-strand conformational polymorphism/heteroduplex analysis to verify the correlation between the observed banding patterns and the sequences at the two SNPs. Over 97% of the samples could be scored for both loci by blinded review by two individuals. The RAD51:135 gc SNP was assayed in some subjects using a standard PCR and BstNI digestion specific for the wild-type "g" allele, using the primers 64F (5'-gggaactgcaactcatctgggtt) and 170R (5'-tgg cac gcg ccc gac) at 200 nM concentration to amplify a 107-bp product. The population allele frequencies for the polymorphisms were estimated by genotyping 40 unrelated Ashkenazi spouses and 62 non-Jewish spouses from the NCI registry families and 79 males from the Washington Ashkenazi Study. The RAD51:135c allele frequency was 0.05 among Jews and 0.07 among non-Jews, and the RAD51:172t allele frequencies were 0.43 and 0.41, respectively. The genotype frequencies did not deviate significantly from Hardy-Weinberg equilibrium.

Statistical Analysis.
To test for association between the RAD51:135 gc SNP and cancer risk among the series of 652 female BRCA1/2 mutation carriers (study group a) for breast cancer analyses, the 345 subjects who had been diagnosed with breast cancer were classified as cases and the remaining 307 subjects as controls. Because analyses of ovarian cancer risk were undertaken after those for breast cancer, we excluded all of the subjects who had developed breast cancer, leaving 44 subjects with ovarian cancer and 263 control subjects with neither breast nor ovarian cancer. A subject’s age was taken as the age at diagnosis for cases and the current age, age at bilateral preventive surgery (mastectomy or oophorectomy), or age at death for controls. The ORs comparing SNP carrier frequency between those with and without cancer were obtained using logistic regression models. All of the analyses were adjusted for age, ethnicity (Jewish, non-Jewish), gene (BRCA1 or BRCA2), and study center, although the estimates changed very little with adjustment. Because observations from related subjects may not be independent, adjusted CLs for all of the ORs and Ps were calculated using a bootstrap resampling technique. Two thousand resamplings of the data, grouped on family, were drawn with replacement (19) . The 2.5% and 97.5% empirical values of the regression coefficients were used as the 95% CLs, and the significance level was calculated as twice the proportion of replicates that resulted in a regression coefficient less than zero.

For subjects from the ovarian cancer case-control study (study group b), we compared the prevalence of the RAD51:135 gc SNP between BRCA1/2 mutation-positive cases versus all of the others with a Mantel-Haenszel OR, adjusted for ethnicity (Ashkenazi/non-Ashkenazi). All of the statistical analyses were performed using S-Plus 2000 Professional (Mathsoft, Inc.).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
By complete sequencing of RAD51 cDNA in 10 individuals, no differences were observed in the amino acid-coding portions of RAD51 (compared with GenBank accession no. D14134.1), but we observed a polymorphism in the 5'UTR at nucleotide position 172 gt. To analyze this polymorphism in our sample of female BRCA1/2 mutation carriers, in which only genomic DNA was available for most, we developed a genomic PCR-based assay that upon sequencing in 10 unrelated individuals from the Center d’Etude du Polymorphisme Humain collection revealed another, less common 5'UTR variant nucleotide at position 135 gc (GenBank accession no. AF233739.1).

To test for association between the SNPs and cancer risk, we compared the frequencies between female BRCA1/2 mutation carriers with and without breast and/or ovarian cancer with the characteristics shown in Table 1 . Approximately one half of the subjects had breast cancer and approximately one third carried a BRCA2 mutation. The average number of subjects/family ranged from one in the Washington Ashkenazi Study group to 3.7 for the Genetic Epidemiology Branch families. In the hypothesis-generating data from NCI, 14 (21%) of the 67 female BRCA1/2 mutation carriers who had developed breast cancer carried at least one RAD51:135c allele, whereas 8 (7%) of 119 subjects without breast cancer carried a "c" allele (adjusted OR, 3.1; 95% CL, 1.1–14; P = 0.04). There was no difference in the frequency of the three genotypes at RAD51:172 gt between breast cancer cases (14% t/t; 49% g/t) and controls (18% t/t; 38% g/t).

The combined data set had sufficient numbers of subjects to perform analyses restricted to subsets of the data (Table 2) . There was a statistically significant increased risk of breast cancer associated with the RAD51:135c allele among the 216 BRCA2 mutation carriers (OR, 3.2; 95% CL, 1.4–40; P = 0.01). The median age at breast cancer diagnosis among BRCA2 mutation carriers and at least one RAD51:135c allele was 37 years versus 41 years for those without the SNP (P = 0.02; two-sided nonparametric median test; Ref. 20 ). The magnitude of the risk was strongest for the two study groups in which all of the subjects were Jewish (Washington Ashkenazi Study and Memorial Sloan Kettering Cancer Center). In analyses restricted to the 400 Jewish subjects, an increased risk was present for BRCA1 and BRCA2 mutation carriers combined, with 13% of breast cancer cases carrying the RAD51:135c versus 7% without breast cancer (OR, 2.4; 95% CL, 1.2–5.8; P = 0.02). The associations among the Jewish subjects were relatively consistent across study centers and were stronger for BRCA2 mutation carriers, but small sample sizes precluded reliable statistical testing of subgroups.

View this table: [in this window] [in a new window]   Table 2 Association between RAD51:135gc SNP and breast cancer risk among BRCA1 and BRCA2 heterozygous mutation carriers

The suggestion of a lower risk of ovarian cancer led us to determine the RAD51:135 gc SNP genotype in a completely different study setting. Among a large group of invasive epithelial ovarian cancer cases and controls from Israel, the RAD51:135c allele was present in 6.5% of 62 BRCA2 mutation-positive cases, 10% of 151 BRCA1 mutation-positive cases, 13% of 304 BRCA1/2-negative cases, and 14% of 221 controls (Table 3) . The OR associated with the RAD51:135c allele, adjusted for ethnicity, was 0.66 (95% CL, 0.4–1.15) for BRCA1/2-positive cases versus all of the other subjects.

View this table: [in this window] [in a new window]   Table 3 Comparison of RAD51:135gc SNP genotypes among subjects in National Israeli Study of Ovarian Cancera

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

We evaluated the two RAD51 SNPs as potential modifying alleles, initially in a series of 186 female BRCA1/2 heterozygous mutation carriers from NCI. Because of the relatively small sample size, we combined BRCA1 and BRCA2 mutation carriers and observed a statistically significant association between the risk of breast cancer and carrying the rarer "c" allele at nucleotide 135 of the RAD51 gene. Female carriers of either a BRCA1 or a BRCA2 mutation who also carried this SNP had about 3-fold increased odds of developing breast cancer compared with BRCA1/2 mutation carriers without the SNP. We attempted to replicate this finding by determining the RAD51:135 gc SNP in an additional set of 446 female BRCA1/2 mutation carriers from three study centers. Analyzing BRCA1/2 mutation carriers together, the association was not confirmed, with the RAD51:135c allele nearly equally frequent among women with and without breast cancer.

The entire group of 652 BRCA1/2 mutation carriers was large enough to conduct analyses of subgroups, and we analyzed BRCA1 and BRCA2 mutation carriers separately. In the hypothesis-generating data set from NCI, the association was stronger among BRCA2 mutation carriers. In the replication sets, although there was clearly no association among the BRCA1 mutation carriers, more BRCA2 mutation carriers with breast cancer (12%) carried the 135c SNP compared to those without breast cancer (8%). In the entire group of 216 BRCA2 mutation carriers studied, carrying the RAD51:135c allele was associated with a significant risk of breast cancer (OR, 3.2; 95% CL, 1.4–40). Because only nonsense, frameshift, or splicing BRCA2 mutations were studied, 26% of the studied mutations would be expected to have lost all of the eight BRC repeats, the regions of BRCA2 involved in the RAD51 interaction (23) , whereas an additional 69%, including the common 6174delT mutation, would be predicted to have lost at least some of the terminal BRC repeats.

We observed the opposite effect with regard to ovarian cancer risk for the RAD51:135 gc SNP. None of the 11 BRCA2 mutation-positive subjects with ovarian cancer (and no breast cancer) carried the RAD51:135c allele, compared with 6% of 84 subjects with neither breast nor ovarian cancer. The RAD51:135c allele was also less common in these two groups of BRCA1 mutation carriers, present in 6% of 33 ovarian cancer cases versus 13% of controls. This apparent lower risk of ovarian cancer was explored further in an entirely different study population. Among 731 subjects from the National Israeli Study of Ovarian Cancer characterized as to BRCA1/2 founder mutations and RAD51:135 gc SNP genotypes, BRCA1/2 mutation-positive ovarian cancer cases were 34% less likely to carry the RAD51:135c allele compared with BRCA1/2 mutation-negative cases and controls, with BRCA2 mutation-positive cases the least likely to carry the SNP. Although not formally statistically significant, the size of the effect was similar to that predicted from the hypothesis-generating observation in the series of female BRCA1/2 mutation carriers.

The populations of BRCA1/2 mutation carriers we studied are not ideal, but given the low frequency of mutations among the general population and the technical difficulties of detecting mutations, optimal epidemiological designs to identify factors that may modify mutation carriers’ cancer risk require inordinately large sample sizes. The female BRCA1/2 mutation carriers consisted predominantly of members of families initially identified in high-risk clinical settings. Almost all of the unaffected mutation carriers were relatives of cancer cases in whom the mutation was initially identified. All of the Washington Ashkenazi Study participants volunteered for a single cross-sectional study. Breast cancer "cases," therefore, were survivors who volunteered after a variable length of time since their diagnosis and were not a random or epidemiological sampling of incident cases. If survival is different between individuals with different RAD51 SNP genotypes, this could lead to differential participation and bias the results. Survival bias should be somewhat less of a problem in the largely family-based study groups, which are followed prospectively and include both living and deceased individuals.

Is the RAD51:135 gc SNP association with cancer risk real? The statistical evidence from this study is not overwhelming, with the initial observation, made by analyzing a combined group BRCA1 and BRCA2 mutation carriers, not confirmed in a replication set of over 400 BRCA1/2 mutation carriers. But the more consistent association across study sites for BRCA2 mutation carriers, the supportive findings in an entirely different epidemiological study group from the National Israeli Ovarian Cancer Study, and the replication of the association among BRCA2 mutation carriers by an independent group, in which 17% of 46 mutation carriers with breast or ovarian cancer from Israel carried the RAD51:135c allele compared with 5% of 41 healthy carriers (24) , suggests that it is.

Biochemical evidence as to how this SNP might affect cancer risk would greatly bolster the association but is lacking. Although there are some known regulatory elements associated with 5'UTRs (25 , 26) , it is not immediately clear how the SNPs identified in this study might affect gene function. One possibility is that it affects mRNA splicing, but we did not observe consistent, alternate reverse transcription-PCR products that correlated with the SNP. Other mechanisms, such as regulation of transcription (e.g., through methylation), translation (e.g., through internal ribosomal entry segments), or mRNA stability, remain to be studied. This polymorphism could also be in linkage disequilibrium with another sequence change in a regulatory region of the RAD51 gene or with another nearby gene that affects the incidence of breast cancer in BRCA1/2 mutation carriers. Studies correlating the presence of the polymorphism with RAD51 expression and function will be needed to support the statistical association we observed.

The RAD51:135 gc SNP was associated with an increased risk of breast cancer and a lower risk of ovarian cancer among the series of female BRCA1/2 mutation carriers studied. This divergence in findings may be attributable to chance or may reflect different biological effects in the two tissues. The differences may also be attributable to the fact that to a large extent breast and ovarian cancer are competing end points. If RAD51 is primarily active in one tissue, e.g., if the SNP is associated with an increased risk of breast cancer, fewer polymorphism carriers would then survive to be diagnosed with ovarian cancer, and one might expect to see opposite associations for the two end points. It is unknown whether the RAD51:135 gc SNP is also associated with an increased breast cancer risk among the majority of women who do not carry BRCA1/2 mutations.

	Acknowledgments

 
We thank Washington Ashkenazi Study investigators Patricia Hartge, Sholom Wacholder, and Lawrence Brody; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer investigators Joe Sambrook, Heather Thorne, Jenny Leary, Judy Kirk, Graham Mann, Ted Edkins, Eric Haan, Geoff Lindeman, Kathy Tucker, and Michael Gattas; Australian Breast Cancer Family Study/Cooperative Family Registry for Breast Cancer Studies investigators John Hopper, Deon Venter, Graham Giles, Margaret McCredie, Melissa Southey, Gillian Dite, and Sarah Steinborner; Australian Jewish Breast Cancer Study investigators Carmel Apicella, Leslie Andrews, and Michael Friedlander; South Australian Clinical Genetics Service investigators Frank Firgaira and Barney Rudzski; and National Israeli Study of Ovarian Cancer investigators Shmuel Anderman, Shaul U. Anteby, Jack Atad, Dan Beck, Uzi Beller, Gilad Ben-Baruch, Walter Gotlieb, Ram Dgani, Amiram Fishman, Alexander Kopmer, Tal Levi, Liat Lerner-Geva, Zohar Liviatan, Joseph Menczer, Moshe Oettinger, Benjamin Piura, David Schneider, Shifra Zohar, Eitan Friedman, Haim Yafe, Yeuda Ben-David, Amiram Baraam, Marko Altaras, and Moshe Ben-Ami for contributing data, Xiaoqing Chen (Queensland Institute of Medical Research, Queensland, Australia) for technical assistance, and Robert Clifford (Laboratory of Population Genetics, NCI) for assistance with sequence analysis.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by the Koodish Foundation, the Queensland Cancer Fund, the Evan M. Frankel Foundation, and the Gloria and Sidney Danziger Foundation.

² Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.

³ Australian Breast Cancer Family Study/Cooperative Family Registry for Breast Cancer Studies.

⁴ Australian Jewish Breast Cancer Study.

⁵ National Israeli Study of Ovarian Cancer.

⁶ To whom requests for reprints should addressed, at Laboratory of Population Genetics, Building 41/D702, 41 Library Drive, Bethesda, MD 20892-5060. Phone: (301) 435-8953; Fax: (301) 435-8963; E-mail: js140a{at}nih.gov

⁷ The abbreviations used are: UTR, untranslated region; SNP, single-nucleotide polymorphism; NCI, National Cancer Institute; OR, odds ratio; CL, confidence limit.

Received 12/31/00; revised 5/11/01; accepted 6/11/01.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M. D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T. R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B. A., Gayther S. A., Zelada-Hedman M., The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet., 62: 676-689, 1998.[Medline]
2. Easton D. F., Ford D., Bishop D. T., The Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am. J. Hum. Genet., 56: 265-271, 1995.[Medline]
3. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336: 1401-1408, 1997.[Abstract/Free Full Text]
4. Thorlacius S., Struewing J. P., Hartge P., Olafsdottir G. H., Sigvaldason H., Tryggvadottir L., Wacholder S., Tulinius H., Eyfjord J. E. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet, 352: 1337-1339, 1998.[Medline]
5. Hopper J. L., Southey M. C., Dite G. S., Jolley D. J., Giles G. G., McCredie M. R. E., Easton D. F., Venter D. J. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein- truncating mutations in BRCA1 and BRCA2. Cancer Epidemiol. Biomark. Prev., 8: 741-747, 1999.[Abstract/Free Full Text]
6. Narod S. A., Ford D., Devilee P., Barkardottir R. B., Lynch H. T., Smith S. A., Ponder B. A., Weber B. L., Garber J. E., Birch J. M., Cornelis R. S., Kelsell D. P., Spurr N. K., Smyth E., Haites N., Sobol H., Bignon Y. J., Chang-Claude J., Hamann U., Lindblom A., Borg A., Piver M. S., Gallion H. H., Struewing J. P., Whittemore A. S., Tonin P., Goldgar D. E., Easton D. F. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am. J. Hum. Genet., 56: 254-264, 1995.[Medline]
7. Phelan C. M., Rebbeck T. R., Weber B. L., Devilee P., Ruttledge M. H., Lynch H. T., Lenoir G. M., Stratton M. R., Easton D. F., Ponder B. A., Cannon A. L., Larsson C., Goldgar D. E., Narod S. A. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat. Genet., 12: 309-311, 1996.[Medline]
8. Rebbeck T. R., Kantoff P. N., Krithivas K., Neuhausen S., Blackwood M. A., Godwin A. K., Daly M. B., Narod S. A., Garber J. E., Lynch H. T., Weber B. L., Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet., 64: 1371-1377, 1999.[Medline]
9. Chen J. J., Silver D., Cantor S., Livingston D. M., Scully R. BRCA1, BRCA2, and RAD51 operate in a common DNA damage response pathway. Cancer Res., 59 (Suppl.): 1752s-1756s, 1999.
10. Baumann P., West S. C. Role of the human RAD51 protein in homologous recombination and double-stranded break repair. Trends Biochem Sci., 23: 247-251, 1998.[Medline]
11. Basile G., Aker M., Mortimer R. K. Nucleotide sequence and transcriptional regulation of the yeast recombinational repair gene RAD51. Mol. Cell. Biol., 12: 3235-3246, 1992.[Abstract/Free Full Text]
12. Boice J. D., Jr., Mandel J. S., Doody M. M. Breast cancer among radiologic technologists. J. Am. Med. Assoc., 274: 394-401, 1995.[Abstract]
13. Struewing J. P., Brody L. C., Erdos M. R., Kase R. G., Giambarresi T. R., Smith S. A., Collins F. S., Tucker M. A. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am. J. Hum. Genet., 57: 1-7, 1995.[Medline]
14. Osborne R. H., Hopper J. L., Kirk J. A., Chenevix-Trench G., Thorne H. J., Sambrook J. F. kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. Med. J. Aust., 172: 463-464, 2000.[Medline]
15. Hopper J. L., Chenevix-Trench G., Jolley D. J., Dite G. S., Jenkins M. A., Venter D. J., McCredie M. R., Giles G. G. Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J. Natl. Cancer Inst. Monogr., 26: 95-100, 1999.
16. Apicella C., Andrews L., Tucker K., Bankier A., Friedlander M., Venter D., Hopper J. Australian Jewish women’s experiences with a breast cancer gene testing program as part of the co-operative family registry for breast cancer studies (CFR-BCS). Am. J. Hum. Genet., 65: 1048 1999.
17. Modan B., Hartge P., Hirsch-Yechezkel G., Chetrit A., Lubin F., Beller U., Ben-Baruch G., Fishman A., Menczer J., Ebbers S. M., Tucker M. A., Wacholder S., Struewing J. P., Friedman E., Piura B. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med., 345: 235-240, 2001.[Abstract/Free Full Text]
18. Fishman A., Dekel E., Chetrit A., Lerner-Geva L., Bar-Am A., Beck D., Beller U., Ben-Baruch G., Piura B., Friedman E., Struewing J. P., Modan B. Patients with double primary tumors in the breast and ovary–clinical characteristics and BRCA1–2 mutations status. Gynecol. Oncol., 79: 74-78, 2000.[Medline]
19. Efron B., Tibshirani R. J. . An Introduction to the Bootstrap, Vol. 57: 436 Chapman & Hall New York 1993.
20. Daniel W. W. . Biostatistics. A Foundation for Analysis in the Health Sciences, 398-401, John Wiley & Sons, Inc. New York 1983.
21. Bell D. W., Wahrer D. C. R., Kang D. H., MacMahon M. S., FitzGerald M. G., Ishioka C., Isselbacher K. J., Krainer M., Haber D. A. Common nonsense mutations in RAD52. Cancer Res., 59: 3883-3888, 1999.[Abstract/Free Full Text]
22. Kato M., Yano K., Matsuo F., Saito H., Katagiri T., Kurumizaka H., Yoshimoto M., Kasumi F., Akiyama F., Sakamoto G., Nagawa H., Nakamura Y., Miki Y. Identification of Rad51 alteration in patients with bilateral breast cancer. J. Hum. Genet., 45: 133-137, 2000.[Medline]
23. Bork P., Blomberg N., Nilges M. Internal repeats in the BRCA2 protein sequence. Nat. Genet., 13: 22-23, 1996.[Medline]
24. Levy-Lahad E., Lahad A., Eisenberg S., Dagan E., Paperna T., Kasinetz L., Catane R., Kaufman B., Beller U., Renbaum P., Gershoni-Baruch R. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc. Natl. Acad. Sci. USA, 98: 3232-3236, 2001.[Abstract/Free Full Text]
25. van der Velden A. W., Thomas A. A. The role of the 5' untranslated region of an mRNA in translation regulation during development. Int. J. Biochem. Cell. Biol., 31: 87-106, 1999.[Medline]
26. Gray N. K. Translational control by repressor proteins binding to the 5'UTR of mRNAs. Methods Mol. Biol., 77: 379-397, 1998.[Medline]

This article has been cited by other articles:

				J. Brooks, R. E. Shore, A. Zeleniuch-Jacquotte, D. Currie, Y. Afanasyeva, K. L. Koenig, A. A. Arslan, P. Toniolo, and I. Wirgin Polymorphisms in RAD51, XRCC2, and XRCC3 Are Not Related to Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 1016 - 1019. [Full Text] [PDF]

				T. Ishida, Y. Takizawa, I. Sakane, and H. Kurumizaka The Lys313 residue of the human Rad51 protein negatively regulates the strand-exchange activity. Genes Cells, January 1, 2008; 13(1): 91 - 103. [Abstract] [Full Text] [PDF]

				J. Lu, L.-E Wang, P. Xiong, E. M. Sturgis, M. R. Spitz, and Q. Wei 172G>T variant in the 5' untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant Carcinogenesis, May 1, 2007; 28(5): 988 - 994. [Abstract] [Full Text] [PDF]

				A. Jakubowska, J. Gronwald, J. Menkiszak, B. Gorski, T. Huzarski, T. Byrski, L. Edler, J. Lubinski, R. J. Scott, and U. Hamann The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 270 - 275. [Abstract] [Full Text] [PDF]

				A. B. Spurdle, A. C. Antoniou, L. Kelemen, H. Holland, S. Peock, M. R. Cook, P. L. Smith, M. H. Greene, J. Simard, M. Plourde, et al. The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 76 - 79. [Abstract] [Full Text] [PDF]

				S. R. Payne and C. J. Kemp Tumor suppressor genetics Carcinogenesis, December 1, 2005; 26(12): 2031 - 2045. [Abstract] [Full Text] [PDF]

				P. M. Webb, J. L. Hopper, B. Newman, X. Chen, L. Kelemen, G. G. Giles, M. C. Southey, G. Chenevix-Trench, and A. B. Spurdle Double-Strand Break Repair Gene Polymorphisms and Risk of Breast or Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 319 - 323. [Abstract] [Full Text] [PDF]

				Y. Takizawa, T. Kinebuchi, W. Kagawa, S. Yokoyama, T. Shibata, and H. Kurumizaka Mutational analyses of the human Rad51-Tyr315 residue, a site for phosphorylation in leukaemia cells Genes Cells, September 1, 2004; 9(9): 781 - 790. [Abstract] [Full Text] [PDF]

				L.-E Wang, M. L. Bondy, H. Shen, R. El-Zein, K. Aldape, Y. Cao, V. Pudavalli, V. A. Levin, W. K. A. Yung, and Q. Wei Polymorphisms of DNA Repair Genes and Risk of Glioma Cancer Res., August 15, 2004; 64(16): 5560 - 5563. [Abstract] [Full Text] [PDF]

				C. Seedhouse, R. Faulkner, N. Ashraf, E. Das-Gupta, and N. Russell Polymorphisms in Genes Involved in Homologous Recombination Repair Interact to Increase the Risk of Developing Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2004; 10(8): 2675 - 2680. [Abstract] [Full Text] [PDF]

				S. Shin and I. M. Verma BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription PNAS, June 10, 2003; 100(12): 7201 - 7206. [Abstract] [Full Text] [PDF]

				A. Jakubowska, S. A. Narod, D. E. Goldgar, M. Mierzejewski, B. Masojc, K. Nej, J. Huzarska, T. Byrski, B. Gorski, and J. Lubinski Breast Cancer Risk Reduction Associated with the RAD51 Polymorphism among Carriers of the BRCA1 5382insC Mutation in Poland Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 457 - 459. [Abstract] [Full Text] [PDF]

				E. L. Goode, C. M. Ulrich, and J. D. Potter Polymorphisms in DNA Repair Genes and Associations with Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1513 - 1530. [Abstract] [Full Text] [PDF]

				K. Y. K. Chan, A. N. Y. Cheung, S.-P. Yip, H.-H. Ko, T.-W. Lai, and U.-S. Khoo Re: Population-Based Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk J Natl Cancer Inst, October 16, 2002; 94(20): 1581 - 1582. [Full Text] [PDF]

				H. W. Mohrenweiser, T. Xi, J. Vazquez-Matias, and I. M. Jones Identification of 127Amino Acid Substitution Variants in Screening 37 DNA Repair Genes in Humans Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1054 - 1064. [Abstract] [Full Text] [PDF]

				W. Burke and M. A. Austin Genetic Risk in Context: Calculating the Penetrance of BRCA1 and BRCA2 Mutations J Natl Cancer Inst, August 21, 2002; 94(16): 1185 - 1187. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, W. W. Articles by Struewing, J. P. Search for Related Content PubMed PubMed Citation Articles by Wang, W. W. Articles by Struewing, J. P.